A Phase 2 Trial of Mosunetuzumab and Zanubrutinib for Patients With Relapsed/Refractory Marginal Zone Lymphoma
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
To assess the efficacy and safety of mosunetuzumab combined with zanubrutinib in patients with relapsed or refractory MZL.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzona histologicznie zmiana chłoniaka strefy marginalnej
- •Wcześniejsze leczenie co najmniej jednym lekiem (w tym lekiem anty-CD20)
- •Wznowa choroby lub brak odpowiedzi na ostatnie leczenie
- •Zaawansowana choroba (stadium II-IV)
- •Wiek 18 lat lub więcej
- •Ogólny stan zdrowia pozwalający na leczenie systemowe
- •Widoczne guzy możliwe do zmierzenia w badaniach obrazowych
- •Potrzeba leczenia systemowego uzasadniona rozmiarem zmian, objawami lub wynikami badań
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 24, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
MD Anderson Cancer Center
Houston, United States
Trial contact
Dai Chihara, MD,PHD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/16/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.